Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H34O2 |
Molecular Weight | 318.4935 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])C[C@H](O)CC[C@]34C
InChI
InChIKey=AURFZBICLPNKBZ-SYBPFIFISA-N
InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1
Molecular Formula | C21H34O2 |
Molecular Weight | 318.4935 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:10:21 UTC 2023
by
admin
on
Sat Dec 16 08:10:21 UTC 2023
|
Record UNII |
S39XZ5QV8Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
426114
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
||
|
FDA ORPHAN DRUG |
399013
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10446
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
S39XZ5QV8Y
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
5324
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
C169815
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
50169
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
DE-17
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
2121777
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
m1537
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000177178
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
DTXSID901016239
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
S39XZ5QV8Y
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
ALLOPREGNANOLONE
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
DB11859
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
516-54-1
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
Brexanolone
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY | |||
|
92786
Created by
admin on Sat Dec 16 08:10:21 UTC 2023 , Edited by admin on Sat Dec 16 08:10:21 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
EXCRETED UNCHANGED |
Following administration of radiolabeled brexanolone, 47% was recovered in feces (primarily as metabolites) and 42% in urine (with less than 1% as unchanged brexanolone).
URINE
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> ACTIVATOR |
MODULATOR
ALLOSTERIC
|
||
|
BINDER->LIGAND |
Plasma protein binding was greater than 99% and is independent of plasma concentrations.
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||